Is DNLI or DRMA more undervalued in 2026?

CirclFi compares Denali Therapeutics Inc. (DNLI) and Dermata Therapeutics, Inc. (DRMA) using 13 institutional-grade valuation models. DNLI has a Quality of Company score of 6.9/10 while DRMA scores 2.8/10.

Which is a better buy — DNLI or DRMA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DNLI and DRMA valuations compare?

DNLI at $20.95 and DRMA at $1.35 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DNLI vs DRMA Valuation Comparison 2026 — Intrinsic Value Analysis

DNLI

Biotechnology

Denali Therapeutics Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$20.95

Last close

Models

12/13

Active

DRMA

Biotechnology

Dermata Therapeutics, Inc.

Quality

2.8

out of 10

Value Trap

LOW

Price

$1.35

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	DNLI Fair Value	DNLI Upside	DRMA Fair Value	DRMA Upside
Bayesian DCF	Intrinsic	$5.78	-72.4%	$1.31	-3.2%
Earnings Power Value	Intrinsic	$9.00	-54.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$5.90	-71.8%	$1.26	-6.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DNLI vs DRMA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DNLI vs DRMA — Which Stock Is More Undervalued?

DNLI scores higher with a 6.9/10 quality rating vs DRMA's 2.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Denali Therapeutics Inc. (DNLI) and Dermata Therapeutics, Inc. (DRMA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DNLI currently trades at $20.95 with a QOC of 6.9/10, while DRMA trades at $1.35 with a QOC of 2.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).